openPR Logo
Press release

CELL LINE DEVELOPMENT SERVICES MARKET TO WITNESS STEADY GROWTH IN THE COMING DECADE

03-20-2018 09:45 AM CET | Health & Medicine

Press release from: Roots Analysis

Roots Analysis has announced the addition of “Cell Line Development Services Market, 2017-2027” report to its list of offerings. The report features an extensive study on the rapidly growing market of cell line development and manufacturing services providers. The report presents an elaborate compilation of research, analysis and opinions on several key aspects of the market.

Akanksha Bhagtani, the principal analyst, said, “The growing pipeline of biological drugs has resulted in a continuous increase in the demand for different types of cell lines. Additionally, the loss of patent exclusivity of several biologics and the entry of numerous biosimilars, and need for cell lines in other areas, such as drug screening, gene functional studies, cell-based assay development, diagnostics and tissue engineering, have resulted in further increase in the demand for different types of cell lines. This presents significant opportunities to cell line development service providers.”

One of the primary objectives of the study was to project the growth of this market segment and evaluate the future prospects of upcoming cell line development technologies / services. Amongst other things, the study highlights the following:
• The current competitive market landscape with respect to key players, along with information on the location of their manufacturing facilities, distribution of cell lines based on their source of origin (mammalian, microbial, insect-derived, avian, marine and reptilian), type of cell lines (recombinant, hybridoma and primary cell lines), affiliated production technologies, purpose of production (R&D, diagnostics, biomanufacturing and tissue engineering), and other associated services (cell line characterization, cell banking, cell bank characterization, process development, cGMP manufacturing of biologics, fill / finish of end products and commercialization of reagents / equipments).
• A detailed analysis of the database presented as three schematic representations; a world map depicting the most active geographies in terms of the presence of cell line development facilities, a heat map representing the distribution of companies on the basis of their location (continent-wise distribution), year of establishment and cell line development capabilities, and a logo landscape highlighting the distribution of companies based on the number of employees and the source of cell lines.
• Elaborate profiles of key industry players that have proprietary technologies for the development of cell lines and offer other services, such as cell line characterization, cell banking and cGMP production of biologics, as well. Each profile features an overview of the company, its financial performance, information on cell line development services and proprietary technology, manufacturing facilities, expansions and collaborations, and a comprehensive future outlook.
• Detailed profiles of non-industry players (cell line repositories) that play an active role in the development of cell lines and offer affiliated services, as well. Each profile features an overview of the repository and a brief description of the cell line development services offered.
• An analysis of the future growth opportunity, segmented by regions, source and grade of cell lines. For the purposes of this analysis, several parameters, such as the number of companies involved, price of cell lines depending (characterized or uncharacterized), source of cell lines, and average number of cell line development projects undertaken by companies in a year, were taken into consideration.

Bhagtani further added, “Among different types of sources used to obtain cell lines, mammalian sources continue to be preferred (~80%); this is followed by microbial cell lines. Overall, the cell line development services market is poised to grow at a steady pace in the coming decade.”

The report highlights the contributions of several players in the field, including those that are listed below:
• Abzena
• Batavia Biosciences
• Celonic
• CMC Biologics
• Cobra Biologics
• Hyprocell
• LFB Biomanufacturing
• Lonza
• ProBioGen
• Selexis
• trenzyme

The opinions and insights discussed in this report were influenced by discussions conducted with industry experts. The report features detailed transcripts of interviews held with Fan Chen (Vice President Bioprocessing, LakePharma), Michael Pointek (Managing Director, Artes Biotechnology), Nienke Smits (Business Development, Modiquest) and Oscar Hoogteijling (Business Development Manager, Bioceros).

For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/cell-line-development-services-market-2017-2027/171.html
or email sales@rootsanalysis.com

Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you'd like us to help you with your growing business needs, get in touch at info@rootsanalysis.com

For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/cell-line-development-services-market-2017-2027/171.html
or email sales@rootsanalysis.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release CELL LINE DEVELOPMENT SERVICES MARKET TO WITNESS STEADY GROWTH IN THE COMING DECADE here

News-ID: 984345 • Views:

More Releases from Roots Analysis

Pharmaceutical Contract Manufacturing Market CAGR To Reach 4.5% between 2025 and 2035, Driven by the Need to Reduce Manufacturing Costs and Speed Up Drug Delivery | Roots Analysis
Pharmaceutical Contract Manufacturing Market CAGR To Reach 4.5% between 2025 and …
According to our latest market report "Pharmaceutical Contract Manufacturing Market by Type of Product Manufactured, Type of API, API Potency, Type of FDF, Dosage Form, Type of Oral Solid, Type of Packaging Offered, Scale of Operation, End User, Geographical Regions and Key Players: Industry Trends and Global Forecasts, till 2035", the pharmaceutical contract manufacturing market is estimated to be USD 100.3 billion in 2025. It is expected to reach USD
Cell Therapy Manufacturing Market CAGR To Exceed 8.25% by 2035, Due to the Growing Demand for Personalized Cell Therapies | Roots Analysis
Cell Therapy Manufacturing Market CAGR To Exceed 8.25% by 2035, Due to the Growi …
According to our latest market report "Cell Therapy Manufacturing Market by Type of Cell Therapy, Source of Cells, Scale of Operation, Type of Manufacturer and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035", the global cell therapy manufacturing market size is projected to reach USD 14,017 million by 2035 from USD 6,343 million in 2025, growing at a CAGR of 8.25% in the forecast period 2025-2035. To request quote
T-Cell Therapy Market Size to Hit USD 20.9 billion by 2035| Exclusive Report by Roots Analysis
T-Cell Therapy Market Size to Hit USD 20.9 billion by 2035| Exclusive Report by …
Cancer is one of the leading causes of mortality across the world. As per the International Agency for Research on Cancer (IARC), by 2040, there are likely to be 27.5 million new cases and 16.3 million deaths related to cancer, annually. Although cancer therapeutics continue to be one of the most active areas, in terms of drug development, there is still a significant unmet need in this domain. In fact,
Cancer Biologics Market: Unmet Need and Treatment Guidelines
Cancer Biologics Market: Unmet Need and Treatment Guidelines
Owing to the increasing mortality rates and growing need for novel modalities to treat oncological disorders, several researchers and industry stakeholders have shifted their focus on the development of safe and effective biologic therapies. Cancer biologics are the class of therapeutic agents, which primarily modulate immune responses or directly inhibits oncogenic pathways in malignancies. These therapies, such as monoclonal antibodies, specifically target tumor-activating genes, facilitate antibody-dependent cellular cytotoxicity and complement

All 5 Releases